Pharma: Other News To Note
Monday, August 6, 2012
GlaxoSmithKline plc (GSK), of London, said it submitted applications in the European Union and the U.S. for use of its BRAF inhibitor dabrafenib as a treatment for adults with unresectable or metastatic melanoma with a BRAF V600 mutation.
Outside of the US
Part of Thomson Reuters
Note: our contact information has changed
In the U.S. and Canada: +1-800-336-4474
Outside the U.S.: +44-203-684-1796
Hours: Monday - Friday, 8:00am - 6:00 pm EST
© 2017 Thomson Reuters. Reproduction, reposting content is strictly prohibited.